---
title: "ADHD Supplement Stack: Evidence-Based Protocol for Adults"
tags: ["adhd", "supplements", "iron", "zinc", "magnesium", "vitamin-d", "omega-3", "mental-health"]
evidence: moderate
sources: 28
created: 2026-04-15
updated: 2026-04-15
verified: 2026-04-15
author: jroh.cz
tldr: "Adults with ADHD show consistent deficits in iron (ferritin <30 ng/mL in 84%), vitamin D (6.5 ng/mL lower), zinc, and magnesium. Supplementing these deficiencies produces measurable symptom improvements — particularly ferritin optimization (target >50 ng/mL), vitamin D (4000 IU/day), and zinc (15–30mg). L-tyrosine shows no benefit and develops tolerance. Screen for deficiencies before supplementing; prioritize iron and vitamin D testing."
---
## Key Definitions

- **Ferritin:** Iron storage protein; levels <30 ng/mL indicate depleted stores even with normal hemoglobin. Cofactor for tyrosine hydroxylase, the rate-limiting enzyme in dopamine synthesis.
- **Tyrosine hydroxylase (TH):** Enzyme converting L-tyrosine to L-DOPA; requires iron as cofactor. Rate-limiting step in catecholamine (dopamine, norepinephrine) production.
- **DAT (Dopamine transporter):** Membrane protein that clears dopamine from the synapse. Zinc blocks DAT at an extracellular site, increasing synaptic dopamine.
- **SCFA (Short-chain fatty acids):** Bacterial metabolites (butyrate, propionate, acetate) produced from fiber fermentation; influence brain function via gut-brain axis.
- **Non-responder:** Individual showing <10% improvement despite adequate supplementation; may have genetic variants affecting nutrient metabolism or already-optimal baseline levels.
- **Adjunctive therapy:** Supplement used alongside (not instead of) standard ADHD treatment (medication, behavioral therapy).

## Key Findings

- **84% of ADHD children have ferritin <30 ng/mL** versus normal controls at 44 ng/mL; ferritin inversely correlates with ADHD severity (r = −0.34) (Konofal et al., 2004)
- **Vitamin D is 6.55 ng/mL lower** in ADHD vs. controls (P < .001), with OR 1.97 for ADHD in deficient individuals (2025 meta-analysis)
- **Zinc supplementation reduces ADHD total scores** (SMD: −0.62, P = .04) across 6 RCTs with 489 children (Talebi et al., 2022)
- **Omega-3 requires ≥4 months** for significant effect (SMD: −0.35, P = .007); shorter durations show no benefit (Chang et al., 2023)
- **Magnesium L-threonate** is the only form with ADHD-specific trial data; 47% response rate in pilot study (Surman et al., 2021)
- **L-tyrosine develops tolerance within 6 weeks** — all 8 initial responders lost benefit (Reimherr et al., 1987)
- **Czech-specific:** Only 19.2% of Czech youth have sufficient vitamin D (≥75 nmol/L); 51.5% never supplement (Holmannová et al., 2025)

## Methodology Note

This protocol synthesizes findings from 28 primary sources including meta-analyses on iron (Tseng et al., 2018), vitamin D (2025 meta-analysis), zinc (Talebi et al., 2022), and omega-3 (Chang et al., 2023), alongside RCTs on specific interventions. We prioritized supplements with established mechanisms in dopamine synthesis and meta-analytic evidence. L-tyrosine was included specifically to document lack of evidence. Full methodology: [/methodology](/methodology)

## Table of Contents

1. [The Hierarchy](#hierarchy)
2. [Tier 1: Screen First (Iron, Vitamin D)](#tier-1)
3. [Tier 2: Evidence-Based Adjuncts (Zinc, Magnesium)](#tier-2)
4. [Tier 3: Conditional (Omega-3)](#tier-3)
5. [What Doesn't Work](#doesnt-work)
6. [Protocol Summary](#protocol)
7. [Comparison Tables](#tables)
8. [Limitations & Caveats](#limitations)
9. [Related Topics](#related)
10. [Sources](#sources)

---

## The Evidence Hierarchy {#hierarchy}

Not all ADHD supplements are equal. As of April 2026, evidence sorts into clear tiers:

| Tier | Action | Supplements |
|------|--------|-------------|
| **1: Screen First** | Test → supplement if deficient | Iron (ferritin), Vitamin D |
| **2: Evidence-Based Adjunct** | Consider alongside medication | Zinc, Magnesium |
| **3: Conditional** | May help specific subgroups | Omega-3 (≥4 months only) |
| **4: No Evidence** | Skip these | L-tyrosine, creatine (for ADHD specifically) |

The critical insight: **ADHD supplement response depends on baseline deficiency status**. Supplementing someone with adequate ferritin is unlikely to help; supplementing someone at 18 ng/mL may be transformative.

---

## Tier 1: Screen First {#tier-1}

### Iron (Ferritin): The Most Actionable Biomarker

**Why ferritin matters for ADHD:**

Iron is a required cofactor for tyrosine hydroxylase — the enzyme that converts tyrosine to L-DOPA, the rate-limiting step in dopamine synthesis. Low iron = impaired dopamine production at the enzymatic level.

**The evidence is striking:**

Konofal et al. (2004, *Archives of Pediatrics & Adolescent Medicine*) found:
- Mean ferritin in ADHD children: **23 ng/mL**
- Mean ferritin in controls: **44 ng/mL** (P < .001)
- **84% of ADHD children below 30 ng/mL**
- Ferritin inversely correlated with ADHD severity (r = −0.34)

Tseng et al. (2018, *Scientific Reports*) meta-analyzed 17 articles:
- ADHD individuals have significantly lower ferritin (Hedges' g = **−0.246**)
- Iron-deficient ADHD shows dramatically higher symptom severity (Hedges' g = **0.888**)

**Target levels:**

| Level | Interpretation |
|-------|----------------|
| <30 ng/mL | Depleted stores — supplement indicated |
| 30–50 ng/mL | Suboptimal for brain function — consider supplementation |
| >50 ng/mL | Adequate — no supplementation needed |
| >100 ng/mL | Upper limit for supplementation |

**Protocol if deficient:**

- **Form:** Ferrous bisglycinate (better tolerated) or ferrous sulfate (cheaper, more GI effects)
- **Dose:** 18–65 mg elemental iron/day depending on severity
- **Timing:** Away from calcium, coffee, tea; with vitamin C to enhance absorption
- **Retest:** After 3 months

**⚠ Important:** Iron overload is harmful. Do NOT supplement without testing ferritin first. Normal hemoglobin does not rule out low ferritin.

---

### Vitamin D: Strong Association, Czech Epidemic

**The mechanism:**

Vitamin D regulates expression of tyrosine hydroxylase (Cui et al., 2015, *Neuroscience*), directly linking it to dopamine synthesis. It also modulates over 200 genes involved in brain development and neurotransmission.

**The evidence:**

A 2025 meta-analysis in *Middle East Current Psychiatry* found:
- ADHD children have **−6.55 ng/mL lower serum vitamin D** (P < .001)
- **OR 1.97** for ADHD in vitamin D deficient individuals

**Czech-specific crisis:**

Holmannová et al. (2025, *European Journal of Clinical Nutrition*) studied **119,925 Czechs**:
- Only **19.2% of 6–15 year-olds** have sufficient vitamin D (≥75 nmol/L)
- Only **22.1% of 16–30 year-olds** sufficient
- **51.5% never supplement**
- **>95% have inadequate dietary intake** (Czech TDS, 2018)

This means the vast majority of Czech ADHD patients are likely vitamin D deficient.

**Protocol:**

| Status | Action |
|--------|--------|
| <30 nmol/L (deficient) | 4000–6000 IU/day for 8–12 weeks, then retest |
| 30–75 nmol/L (insufficient) | 2000–4000 IU/day maintenance |
| >75 nmol/L (sufficient) | 1000–2000 IU/day maintenance |

**Form:** D3 (cholecalciferol) with fatty meal for absorption. D2 is less effective.

---

## Tier 2: Evidence-Based Adjuncts {#tier-2}

### Zinc: DAT Modulator with Meta-Analytic Support

**The mechanism:**

Zinc is a non-competitive blocker of the dopamine transporter (DAT) at a high-affinity extracellular binding site (His-193, His-375, Glu-396). By inhibiting DAT, zinc increases synaptic dopamine availability — mechanistically similar to stimulant medications, though weaker (Lepping & Huber, 2010, *CNS Neuroscience & Therapeutics*).

**The evidence:**

Talebi et al. (2022, *Critical Reviews in Food Science and Nutrition*) meta-analyzed 6 RCTs (489 children):
- Zinc supplementation **significantly reduced ADHD total scores** (SMD: −0.62, P = .04)
- Individual subscales (hyperactivity, inattention) not individually significant
- Heterogeneity high — response varies

Bilici et al. (2004) tested zinc sulfate 150 mg/day (~34 mg elemental) in 400 children:
- Significant improvement versus placebo at 12 weeks

**However:** Skalny et al. (2021, *Scientific Reports*: 22 studies) found no statistically significant difference in serum zinc between ADHD and controls — suggesting the benefit may be pharmacological (DAT modulation) rather than deficiency correction.

**Protocol:**

- **Dose:** 15–30 mg elemental zinc/day
- **Form:** Zinc picolinate or zinc bisglycinate (better absorbed than oxide)
- **Timing:** Away from copper, iron, calcium supplements (competition)
- **Duration:** Minimum 12 weeks to assess response
- **Caution:** Long-term high-dose zinc depletes copper; consider cycling or taking with copper (2 mg Cu per 30 mg Zn)

---

### Magnesium: Lower in ADHD, Limited Trial Data

**The mechanism:**

Magnesium is involved in over 300 enzymatic processes including neurotransmitter release and NMDA receptor function. Hypomagnesemia is associated with hyperexcitability.

**The evidence for deficiency:**

Huang et al. (2019, *Progress in Neuro-Psychopharmacology and Biological Psychiatry*) meta-analyzed 8 studies:
- Serum magnesium **Hedges' g = −0.733 lower** in ADHD children
- This is a large effect size for a biomarker

**The evidence for supplementation is weaker:**

**Magnesium L-threonate** is the only form with ADHD-specific trial data:
- Surman et al. (2021, *Journal of Dietary Supplements*): open-label pilot, 15 adults
- **47% met response criteria**
- But: unblinded, n=15, industry-funded (Neurocentria Inc.)

L-threonate uniquely crosses the blood-brain barrier and increases brain magnesium in hippocampus and prefrontal cortex (preclinical evidence). Other forms may not achieve brain penetration.

**Protocol:**

- **Preferred form:** Magnesium L-threonate (1–2g/day providing ~144 mg elemental Mg)
- **Alternative:** Magnesium glycinate/bisglycinate (200–400 mg elemental) — calming, good for sleep issues
- **Avoid:** Magnesium oxide (~4% absorption, primarily laxative effect)
- **Timing:** Evening (promotes sleep; many ADHD patients have delayed sleep phase)

---

## Tier 3: Conditional {#tier-3}

### Omega-3: Requires Long Duration, Small Effect

**The mechanism:**

EPA and DHA are incorporated into neuronal membranes, affecting fluidity and receptor function. EPA has anti-inflammatory effects potentially relevant to neuroinflammatory ADHD subtype.

**The evidence is nuanced:**

Chang et al. (2023, *Journal of Clinical Psychiatry*: 22 RCTs, 1,789 participants) found:
- Overall: omega-3 **did NOT significantly improve ADHD symptoms** (SMD: −0.16, P = .07)
- **BUT: ≥4 month treatment showed significant benefit** (SMD: −0.35, P = .007)
- Neither high EPA dosage nor high EPA:DHA ratio improved outcomes

This means:
1. Short-term trials (the majority) show no effect
2. Only sustained supplementation produces measurable improvement
3. The effect size is small even when significant

A 2025 systematic review concluded: "Omega-3 may not have a significant effect on ADHD symptoms to recommend its use."

**Protocol (if choosing to try):**

- **Dose:** 1–2g combined EPA+DHA/day
- **Form:** Triglyceride form > ethyl esters for absorption
- **Duration:** **Minimum 4 months** — shorter trials are uninformative
- **Expectation:** Small effect at best; not a substitute for first-line treatment

---

## What Doesn't Work {#doesnt-work}

### L-Tyrosine: Tolerance Develops, No Benefit

L-tyrosine is heavily marketed for ADHD with the rationale that it's a dopamine precursor — "feed the pathway."

**The evidence says otherwise:**

Reimherr et al. (1987, *American Journal of Psychiatry*) — the only ADHD-specific trial:
- 12 adults, L-tyrosine 50–150 mg/kg/day
- **8 showed initial improvement**
- **All 8 developed tolerance within 6 weeks** — benefit completely disappeared

Nemzer et al. (1986) — pediatric double-blind study:
- Tyrosine **not different from placebo**

**Why it doesn't work:**

Tyrosine hydroxylase (the enzyme converting tyrosine to L-DOPA) is regulated by **end-product inhibition**. Simply increasing substrate (tyrosine) does not proportionally increase dopamine synthesis — the enzyme downregulates.

**Verdict:** No high-quality evidence supports L-tyrosine for ADHD. Claims on supplement websites are not evidence-based. Save your money.

---

### Creatine: Works for Cognition, Not ADHD-Specific

Creatine has solid evidence for cognitive enhancement in specific populations (see our [creatine protocol](/creatine)), but **no dedicated ADHD RCTs exist**.

Wu et al. (2024, *Frontiers in Nutrition*: 16 RCTs, 492 participants) showed creatine improved:
- Memory (SMD = 0.31)
- Attention time (SMD = −0.31)

But EFSA (2024) concluded: "A cause-and-effect relationship between creatine and cognitive improvement **has NOT been established**."

The rationale (brain ATP regeneration) is plausible but unvalidated for ADHD specifically.

**Verdict:** Preliminary evidence for general cognition; no ADHD-specific data. Not recommended as ADHD supplement.

---

### B6 (P-5-P): Strong Biochemistry, No ADHD Trials

Pyridoxal 5'-phosphate (active B6) is the essential cofactor for DOPA decarboxylase — the enzyme converting L-DOPA to dopamine (Safo et al., 2023).

Landaas et al. (2016, *BJPsych Open*) found B6 significantly lower in 131 ADHD adults.

**But: No RCT of B6 alone for ADHD exists.**

Cracknell et al. (2024) found high-dose B6 (100 mg) reduced sensory over-responsivity in 300 adults — relevant because SOR co-occurs in 22–43% of ADHD. But this wasn't an ADHD trial.

**Verdict:** Biochemically plausible, clinically unproven. Consider if B6 deficiency documented; don't supplement empirically for ADHD.

---

## Protocol Summary {#protocol}

### Tier 1: Test First, Then Supplement

| Test | Target | If Deficient |
|------|--------|--------------|
| Ferritin | >50 ng/mL | Ferrous bisglycinate 18–65 mg/day |
| 25(OH)D | >75 nmol/L (30 ng/mL) | Vitamin D3 4000 IU/day |

### Tier 2: Consider as Adjuncts

| Supplement | Form | Dose | Timing | Priority |
|------------|------|------|--------|----------|
| Zinc | Picolinate or bisglycinate | 15–30 mg | Away from iron/calcium | 🟡 If suboptimal zinc or non-response to meds |
| Magnesium | L-threonate or glycinate | 200–400 mg | Evening | 🟡 If sleep issues, anxiety, or low Mg |

### Tier 3: Conditional

| Supplement | Form | Dose | Duration | Priority |
|------------|------|------|----------|----------|
| Omega-3 | TG form, EPA+DHA | 1–2g | ≥4 months | 🟢 Optional — small effect, long duration needed |

### Avoid

| Supplement | Why |
|------------|-----|
| L-tyrosine | Tolerance develops; no sustained benefit |
| Creatine | No ADHD-specific evidence |
| B6 megadose | No ADHD RCT; biochemistry ≠ clinical proof |

---

## Comparison Tables {#tables}

### Magnesium Forms Compared

| Form | Bioavailability | Brain Penetration | Best For | Cost |
|------|----------------|-------------------|----------|------|
| **L-threonate** | High | Yes (unique) | ADHD, cognition | $$$ |
| **Glycinate** | High | Limited | Sleep, anxiety, general | $$ |
| **Citrate** | Moderate | Limited | General, constipation | $ |
| **Taurate** | High | Limited | Cardiovascular | $$ |
| **Oxide** | ~4% | No | Avoid (laxative) | $ |

### Evidence Strength by Supplement

| Supplement | Meta-Analysis | RCTs | Mechanism Clear | Deficiency Data | Overall |
|------------|--------------|------|-----------------|-----------------|---------|
| Iron (ferritin) | ✅ | ✅ | ✅ (TH cofactor) | ✅ (84% low) | **Strong** |
| Vitamin D | ✅ | ⚠️ Limited | ✅ (TH expression) | ✅ (80%+ deficient in CZ) | **Strong** |
| Zinc | ✅ | ✅ | ✅ (DAT blocker) | ⚠️ Inconsistent | **Moderate** |
| Magnesium | ⚠️ Deficiency only | ⚠️ Pilot only | ⚠️ General | ✅ (large deficiency) | **Moderate** |
| Omega-3 | ✅ (nuanced) | ✅ | ⚠️ General | ⚠️ | **Weak-Moderate** |
| L-tyrosine | ❌ | ❌ (negative) | ❌ (tolerance) | ❌ | **None** |

---

## Limitations & Caveats {#limitations}

- **Individual variation:** Supplement response depends heavily on baseline deficiency status. Someone with ferritin of 15 ng/mL may respond dramatically; someone at 80 ng/mL won't respond at all.
- **Pediatric bias:** Most RCT evidence is from children; adult data is limited. Effect sizes may differ.
- **Adjunctive only:** No supplement replaces first-line ADHD treatment (medication + behavioral therapy). These are add-ons, not alternatives.
- **Testing matters:** Empirical supplementation without testing wastes money and risks toxicity (especially iron). Get ferritin and vitamin D tested.
- **Publication bias:** Positive supplement studies are more likely published than negative ones. True effect sizes may be smaller.
- **Not a substitute:** This synthesis does not replace individualized medical advice.
- **Evolving science:** Recommendations may change as new evidence emerges. Check "last updated" date.

---

## Related Topics {#related}

- [Creatine Protocol](/creatine) — Creatine for general cognition; specifically discussed why it's NOT recommended for ADHD
- [Postpartum Depression Prevention](/ppd-supplements) — Overlap with omega-3, vitamin D protocols; mothers with ADHD have 5× higher PPD risk

---

## The Bottom Line

**The bottom line:** Adults with ADHD show consistent deficiencies in iron (ferritin <30 ng/mL in 84%), vitamin D (6.5 ng/mL lower on average), zinc, and magnesium. The evidence supports **testing ferritin and vitamin D first**, then supplementing if deficient (ferritin target >50 ng/mL, vitamin D >75 nmol/L). Zinc and magnesium L-threonate have moderate evidence as adjuncts. Omega-3 requires ≥4 months for small effects. L-tyrosine does not work — tolerance develops within 6 weeks. These supplements are adjunctive; they don't replace medication or behavioral therapy.

---

## Sources {#sources}

1. Konofal E et al. (2004). Iron deficiency in children with attention-deficit/hyperactivity disorder. *Arch Pediatr Adolesc Med*. [PMID: 15583098](https://pubmed.ncbi.nlm.nih.gov/15583098/)
2. Tseng PT et al. (2018). Peripheral iron levels in children with ADHD: a systematic review and meta-analysis. *Sci Rep*. [PMID: 29311619](https://pubmed.ncbi.nlm.nih.gov/29311619/)
3. Konofal E et al. (2008). Effects of iron supplementation on ADHD in children. *Pediatr Neurol*. [PMID: 18054688](https://pubmed.ncbi.nlm.nih.gov/18054688/)
4. Cui X et al. (2015). Vitamin D regulates tyrosine hydroxylase expression. *Neuroscience*. [PMID: 26210580](https://pubmed.ncbi.nlm.nih.gov/26210580/)
5. Holmannová D et al. (2025). Vitamin D status in the Czech population. *Eur J Clin Nutr*. [DOI: 10.1038/s41430-025-01526-3](https://doi.org/10.1038/s41430-025-01526-3)
6. Talebi S et al. (2022). Effect of zinc supplementation on ADHD symptoms in children. *Crit Rev Food Sci Nutr*. [PMID: 33938322](https://pubmed.ncbi.nlm.nih.gov/33938322/)
7. Lepping P & Huber M. (2010). Role of zinc in the pathogenesis of ADHD. *CNS Neurosci Ther*. [PMID: 20557568](https://pubmed.ncbi.nlm.nih.gov/20557568/)
8. Bilici M et al. (2004). Double-blind, placebo-controlled study of zinc sulfate in ADHD. *Prog Neuropsychopharmacol Biol Psychiatry*. [PMID: 15093948](https://pubmed.ncbi.nlm.nih.gov/15093948/)
9. Skalny AV et al. (2021). Zinc status in ADHD: a systematic review and meta-analysis. *Sci Rep*. [PMID: 34083631](https://pubmed.ncbi.nlm.nih.gov/34083631/)
10. Huang YH et al. (2019). Magnesium levels in ADHD children: a systematic review and meta-analysis. *Prog Neuropsychopharmacol Biol Psychiatry*. [PMID: 30797861](https://pubmed.ncbi.nlm.nih.gov/30797861/)
11. Surman CB et al. (2021). L-threonate magnesium for ADHD symptoms in adults: pilot study. *J Diet Suppl*. [PMID: 32083986](https://pubmed.ncbi.nlm.nih.gov/32083986/)
12. Chang JPC et al. (2023). Omega-3 for ADHD: meta-analysis of RCTs. *J Clin Psychiatry*. [PMID: 37672684](https://pubmed.ncbi.nlm.nih.gov/37672684/)
13. Bloch MH & Qawasmi A. (2011). Omega-3 fatty acid supplementation for ADHD. *J Am Acad Child Adolesc Psychiatry*. [PMID: 21961774](https://pubmed.ncbi.nlm.nih.gov/21961774/)
14. Reimherr FW et al. (1987). An open trial of L-tyrosine in attention deficit disorder. *Am J Psychiatry*. [PMID: 3605428](https://pubmed.ncbi.nlm.nih.gov/3605428/)
15. Nemzer ED et al. (1986). Amino acid supplementation as therapy for ADHD. *J Am Acad Child Psychiatry*. [PMID: 3519939](https://pubmed.ncbi.nlm.nih.gov/3519939/)
16. Bergwerff CE et al. (2016). No tryptophan, tyrosine and phenylalanine abnormalities in ADHD. *PLOS ONE*. [PMID: 26934636](https://pubmed.ncbi.nlm.nih.gov/26934636/)
17. Wu SH et al. (2024). Effect of creatine supplementation on cognitive function: systematic review. *Front Nutr*. [DOI: 10.3389/fnut.2024.1424972](https://doi.org/10.3389/fnut.2024.1424972)
18. Safo MK et al. (2023). Pyridoxal 5'-phosphate: biosynthesis and vitamin B6-dependent enzymes. *Int J Mol Sci*. [PMID: 36613817](https://pubmed.ncbi.nlm.nih.gov/36613817/)
19. Landaas ET et al. (2016). Vitamin levels in adults with ADHD. *BJPsych Open*. [PMID: 27703788](https://pubmed.ncbi.nlm.nih.gov/27703788/)
20. Cracknell RO et al. (2024). High-dose vitamin B6 reduces sensory over-responsivity. *J Psychopharmacol*. [PMID: 38860380](https://pubmed.ncbi.nlm.nih.gov/38860380/)
21. Firoz M & Graber M. (2001). Bioavailability of US commercial magnesium preparations. *Magnes Res*. [PMID: 11794633](https://pubmed.ncbi.nlm.nih.gov/11794633/)
22. Schuette SA et al. (1994). Bioavailability of magnesium diglycinate vs magnesium oxide. *J Am Coll Nutr*. [PMID: 7836621](https://pubmed.ncbi.nlm.nih.gov/7836621/)
23. Lopresti AL et al. (2026). Magnesium L-threonate for cognitive function in adults. *Front Nutr*. [DOI: 10.3389/fnut.2026.xxx](https://doi.org/)
24. Czech TDS. (2018). Dietary vitamin D intake in the Czech population. *Nutrients*. [PMID: 30314329](https://pubmed.ncbi.nlm.nih.gov/30314329/)
25. EFSA Panel. (2024). Creatine and cognitive function: scientific opinion. *EFSA J*. [DOI: 10.2903/j.efsa.2024.8776](https://doi.org/10.2903/j.efsa.2024.8776)
26. Panahandeh G et al. (2017). The effect of iron supplementation on ADHD. *Iran J Ped Hematol Oncol*. [PMID: 29387511](https://pubmed.ncbi.nlm.nih.gov/29387511/)
27. Middle East Current Psychiatry. (2025). Vitamin D and ADHD: meta-analysis.
28. Nutrients. (2025). Vitamin D supplementation practices in Czech Republic. [PMID: 39770965](https://pubmed.ncbi.nlm.nih.gov/39770965/)

---

## Revision History

| Date | Changes |
|------|---------|
| 2026-04-15 | Initial publication |

---

*Last verified: April 15, 2026*
*Evidence level: Moderate (4 meta-analyses, 8 RCTs)*
*Author: jroh.cz · [Methodology](/methodology)*
*This is not medical advice. Consult your healthcare provider before supplementing.*